Melanoma news from FierceBiotech
News
Medarex shares slide on news of drug app delay
Shares of Medarex slipped seven percent this morning as investors digested Friday's announcement that its application for a new cancer drug will be delayed into 2009. The developer says that the FDA Read more...
ALSO NOTED: US Oncology's CFO retires; Profits rise at Novartis, Merck, Lilly; and much more...
> US Oncology's CFO Rick McCook is resigning to explore opportunities in a retail or manufacturing business. Read more...
Pfizer halts Phase III cancer trial on poor results
Pfizer's big push into cancer drugs has hit a snag. The company announced that it is halting a late-stage trial of tremelimumab for advanced melanoma after researchers concluded it was no more Read more...
Morphotek licenses anti-cancer antibody
Morphotek has inked a deal with Human Monoclonals International to get rights to a human monoclonal IgM antibody that is specific to a cancer cell surface antigen. The company hopes to develop a lead Read more...
Adherex's melanoma drug earns orphan status
North Carolina-based Adherex Technologies has won orphan drug designation from the FDA for its experimental melanoma therapy ADH-1. The drug is currently in Phase IIb trials in combination with Read more...
Antigenics' cancer vax gets mixed Phase III results
Antigenics' cancer vaccine Oncophage failed to meet its primary endpoint of overall Read more...
IDM outlines big layoff in restructuring plan
Two weeks after it was jilted in a key drug collaboration deal, IDM Pharma Read more...
AstraZeneca drops cancer program after Phase II failure
AstraZeneca says it won't take the advanced melanoma drug AZD6244--licensed from Array BioPharma--into late stage trials after seeing the program flunk Phase II. Researchers said they could see no Read more...
Medarex shares dive after a cancer trial failure
Shares of Medarex took a dive in after-hours trading after the biotech announced that the cancer drug ipilimumab--Read more...
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends